Literature DB >> 7518195

Absence of HLA class I expression by Reed-Sternberg cells.

S Poppema1, L Visser.   

Abstract

The reactive cell population in Hodgkin's disease consists of predominantly CD4+ helper T cells and lacks CD8+ cytotoxic T cells and natural killer cells. This lack of a CD8+ response is surprising in view of the expression of the latent Epstein-Barr viral protein LMP by Reed-Sternberg cells in many cases of Hodgkin's disease, Deficient HLA class I expression would be one possible mechanism to avoid a CD8+ cytotoxic immune response. To test this possibility we studied the expression of HLA class I and II determinants on Reed-Sternberg cells in tissue sections and cell suspensions of Hodgkin's disease. Frozen tissue sections of 40 cases and cytocentrifuge preparations from cell suspensions of 10 lymph nodes involved by Hodgkin's disease were studied with monoclonal antibodies reactive with HLA determinants. As a control frozen tissue sections of two cases of infectious mononucleosis were studied. Careful examination of the tissue sections and subsequently of cytospins of cell suspensions showed that the Reed-Sternberg cells frequently lacked HLA class I but showed strong staining for HLA class II. Absence of HLA class I expression on Reed-Sternberg cells and their variants provides an explanation for the lack of a CD8+ cytotoxic immune response against antigens expressed on Reed-Sternberg cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7518195      PMCID: PMC1887312     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  31 in total

Review 1.  Biology of Hodgkin's disease.

Authors:  S Poppema; J Kaleta; B Hepperle; L Visser
Journal:  Ann Oncol       Date:  1992-09       Impact factor: 32.976

2.  A quantitative comparison of T-cell subsets in Hodgkin's disease and reactive hyperplasia. Frozen section immunohistochemistry.

Authors:  J M Martin; R A Warnke
Journal:  Cancer       Date:  1984-06-01       Impact factor: 6.860

3.  Displacement of T lymphocytes with the 'Helper/Inducer' phenotype from peripheral blood to lymphoid organs in untreated patients with Hodgkin's disease.

Authors:  S Romagnani; G F Del Prete; E Maggi; A Bosi; F Bernardi; P Ponticelli; S Di Lollo; M Ricci
Journal:  Scand J Haematol       Date:  1983-10

4.  Immunohistochemical analysis of the distribution of lymphocyte subpopulations in Hodgkin's disease.

Authors:  M J Borowitz; B P Croker; R S Metzgar
Journal:  Cancer Treat Rep       Date:  1982-04

5.  Tumorigenicity of cells transformed by adenovirus type 12 by evasion of T-cell immunity.

Authors:  R Bernards; P I Schrier; A Houweling; J L Bos; A J van der Eb; M Zijlstra; C J Melief
Journal:  Nature       Date:  1983 Oct 27-Nov 2       Impact factor: 49.962

6.  Major histocompatibility antigens and mononuclear inflammatory infiltrate in benign nevomelanocytic proliferations and malignant melanoma.

Authors:  D J Ruiter; A K Bhan; T J Harrist; A J Sober; M C Mihm
Journal:  J Immunol       Date:  1982-12       Impact factor: 5.422

7.  Two neoplastic cell lines with unique features derived from Hodgkin's disease.

Authors:  M Schaadt; V Diehl; H Stein; C Fonatsch; H H Kirchner
Journal:  Int J Cancer       Date:  1980-12-15       Impact factor: 7.396

8.  Expression of class I major histocompatibility antigens switched off by highly oncogenic adenovirus 12 in transformed rat cells.

Authors:  P I Schrier; R Bernards; R T Vaessen; A Houweling; A J van der Eb
Journal:  Nature       Date:  1983 Oct 27-Nov 2       Impact factor: 49.962

9.  In situ immunologic characterization of cellular constituents in lymph nodes and spleens involved by Hodgkin's disease.

Authors:  S Poppema; A K Bhan; E L Reinherz; M R Posner; S F Schlossman
Journal:  Blood       Date:  1982-02       Impact factor: 22.113

10.  Distribution of T-lymphocyte subsets in Hodgkin's disease characterized by monoclonal antibodies.

Authors:  M S Dorreen; J A Habeshaw; P F Wrigley; T A Lister
Journal:  Br J Cancer       Date:  1982-04       Impact factor: 7.640

View more
  9 in total

1.  Immune escape mechanisms in ALCL.

Authors:  J J Oudejans; R L ten Berge; C J L M Meijer
Journal:  J Clin Pathol       Date:  2003-06       Impact factor: 3.411

2.  The role of human leucocyte antigen genes in the development of malignant disease.

Authors:  W M Howell; D B Jones
Journal:  Clin Mol Pathol       Date:  1995-12

3.  CD8(+) T cells in Hodgkin's disease tumor tissue are a polyclonal population with limited clonal expansion but little evidence of selection by antigen.

Authors:  K Willenbrock; A Roers; B Blöhbaum; K Rajewsky; M L Hansmann
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

4.  HLA antigen expression in enteropathy associated T cell lymphoma.

Authors:  M Ashton-Key; N Singh; L X Pan; M E Smith
Journal:  J Clin Pathol       Date:  1996-07       Impact factor: 3.411

Review 5.  Role of immune escape mechanisms in Hodgkin's lymphoma development and progression: a whole new world with therapeutic implications.

Authors:  Luis de la Cruz-Merino; Marylène Lejeune; Esteban Nogales Fernández; Fernando Henao Carrasco; Ana Grueso López; Ana Illescas Vacas; Mariano Provencio Pulla; Cristina Callau; Tomás Álvaro
Journal:  Clin Dev Immunol       Date:  2012-08-15

6.  Assessment of cytotoxic T-lymphocyte phenotype using the specific markers granzyme B and TIA-1 in cervical neoplastic lesions.

Authors:  H J Bontkes; T D de Gruijl; J M Walboomers; A J van den Muysenberg; A W Gunther; R J Scheper; C J Meijer; J A Kummer
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

Review 7.  Immunological deregulation in classic hodgkin lymphoma.

Authors:  Alessandra Romano; Calogero Vetro; Giovanni Caocci; Marianna Greco; Nunziatina Laura Parrinello; Francesco Di Raimondo; Giorgio La Nasa
Journal:  Mediterr J Hematol Infect Dis       Date:  2014-06-01       Impact factor: 2.576

8.  HLA-G+3027 polymorphism is associated with tumor relapse in pediatric Hodgkin's lymphoma.

Authors:  Valli De Re; Laura Caggiari; Lara Mussolin; Emanuele Stefano d'Amore; Barbara Famengo; Mariangela De Zorzi; Lia Martina; Caterina Elia; Marta Pillon; Nicola Santoro; Paola Muggeo; Salvatore Buffardi; Maurizio Bianchi; Alessandra Sala; Piero Farruggia; Luciana Vinti; Edgardo D Carosella; Roberta Burnelli; Maurizio Mascarin
Journal:  Oncotarget       Date:  2017-11-18

Review 9.  Combining low-dose or metronomic chemotherapy with anticancer vaccines: A therapeutic opportunity for lymphomas.

Authors:  Heng Sheng Sow; Stephen R Mattarollo
Journal:  Oncoimmunology       Date:  2013-11-05       Impact factor: 8.110

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.